ID

30575

Description

A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00454532

Link

https://clinicaltrials.gov/show/NCT00454532

Keywords

Versions (2)
  1. 6/16/18 6/16/18 -
  2. 6/16/18 6/16/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

June 16, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Metastatic Breast Cancer NCT00454532

English

Eligibility Metastatic Breast Cancer NCT00454532

1 forms  
Criteria
Description

Criteria

women 18 years or older
Description

Gender | Age

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
histologically confirmed breast cancer
Description

Breast Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0678222
clinical evidence of metastatic (stage iv) metastasis (other than bone metastasis)
Description

Secondary malignant neoplasm of female breast | Exception Secondary malignant neoplasm of bone

Data type

boolean

Alias
UMLS CUI [1]
C0346993
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0153690
availability of estrogen and progesterone receptor status
Description

Availability of Estrogen Receptor Status | Availability of Progesterone Receptor Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C1516974
UMLS CUI [2,1]
C0470187
UMLS CUI [2,2]
C1514471
at least one measurable disease site defined by recist criteria, 30 days prior to study therapy
Description

Measurable Disease Site Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1515974
UMLS CUI [1,3]
C1265611
for the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. for the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
Description

Phase Number | Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of female breast

Data type

boolean

Alias
UMLS CUI [1,1]
C0205390
UMLS CUI [1,2]
C0237753
UMLS CUI [2,1]
C0677881
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0346993
life expectancy ≥ 12 weeks
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
eastern cooperative oncology group performance status ≤2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
Description

Childbearing Potential Contraceptive methods Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
key exclusion criteria:
Description

Exclusion Criteria Main

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
inability to understand/unwillingness to sign a written informed consent
Description

Informed Consent Unable | Informed Consent Unwilling

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0558080
any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
Description

Adverse effects Chemotherapy Related | Adverse effects Therapeutic radiology procedure Related | Adverse effects Biological treatment Related | Adverse effects Hormone Therapy Related | Resolution failed

Data type

boolean

Alias
UMLS CUI [1,1]
C0879626
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C0439849
UMLS CUI [2,1]
C0879626
UMLS CUI [2,2]
C1522449
UMLS CUI [2,3]
C0439849
UMLS CUI [3,1]
C0879626
UMLS CUI [3,2]
C1531518
UMLS CUI [3,3]
C0439849
UMLS CUI [4,1]
C0879626
UMLS CUI [4,2]
C0279025
UMLS CUI [4,3]
C0439849
UMLS CUI [5,1]
C1514893
UMLS CUI [5,2]
C0231175
currently using an investigational agent
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
clinically significant gastrointestinal abnormalities
Description

Abnormality of the gastrointestinal tract

Data type

boolean

Alias
UMLS CUI [1]
C4023588
currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
Description

Coumadin Dose Therapeutic | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C0699129
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0302350
UMLS CUI [2]
C0013230
concurrent palliative radiation or anti-cancer treatment
Description

Palliative Radiation Therapy | Cancer treatment

Data type

boolean

Alias
UMLS CUI [1]
C3898008
UMLS CUI [2]
C0920425
women who report pregnancy, are breast-feeding or have a positive pregnancy test
Description

Pregnancy | Breast Feeding | Pregnancy test positive

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0240802
Back to the top of the page

Similar models

Eligibility Metastatic Breast Cancer NCT00454532

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Gender | Age
Item
women 18 years or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Breast Carcinoma
Item
histologically confirmed breast cancer
boolean
C0678222 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Exception Secondary malignant neoplasm of bone
Item
clinical evidence of metastatic (stage iv) metastasis (other than bone metastasis)
boolean
C0346993 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
Availability of Estrogen Receptor Status | Availability of Progesterone Receptor Status
Item
availability of estrogen and progesterone receptor status
boolean
C0470187 (UMLS CUI [1,1])
C1516974 (UMLS CUI [1,2])
C0470187 (UMLS CUI [2,1])
C1514471 (UMLS CUI [2,2])
Measurable Disease Site Quantity
Item
at least one measurable disease site defined by recist criteria, 30 days prior to study therapy
boolean
C1513041 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Phase Number | Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of female breast
Item
for the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. for the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
boolean
C0205390 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0346993 (UMLS CUI [2,3])
Life Expectancy
Item
life expectancy ≥ 12 weeks
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group performance status ≤2
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Contraceptive methods Quantity
Item
women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Informed Consent Unable | Informed Consent Unwilling
Item
inability to understand/unwillingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
Adverse effects Chemotherapy Related | Adverse effects Therapeutic radiology procedure Related | Adverse effects Biological treatment Related | Adverse effects Hormone Therapy Related | Resolution failed
Item
any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
boolean
C0879626 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0879626 (UMLS CUI [3,1])
C1531518 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0879626 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C1514893 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
Investigational New Drugs
Item
currently using an investigational agent
boolean
C0013230 (UMLS CUI [1])
Abnormality of the gastrointestinal tract
Item
clinically significant gastrointestinal abnormalities
boolean
C4023588 (UMLS CUI [1])
Coumadin Dose Therapeutic | Investigational New Drugs
Item
currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
boolean
C0699129 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0302350 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2])
Palliative Radiation Therapy | Cancer treatment
Item
concurrent palliative radiation or anti-cancer treatment
boolean
C3898008 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
Pregnancy | Breast Feeding | Pregnancy test positive
Item
women who report pregnancy, are breast-feeding or have a positive pregnancy test
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0240802 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial